Annie Luetkemeyer

Clinical Professor

HIV, Infectious Disease, and Global Medicine, Infectious Diseases

Fellowship, 2007 - Infectious Diseases, University of California, San Francisco
2006 - Advance Training in Clinical Research, University of California, San Francisco
2003 - Internal Medicine, University of California, San Francisco
2002 - Internal Medicine, University of California, San Francisco
MD, 1999 - Medicine, Harvard Medical School
AB, 1994 - American Studies, Stanford University
  1. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
  2. Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence.
  3. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
  4. A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome.
  5. Localized US Efforts to Eliminate Hepatitis C.
  6. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
  7. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.
  8. Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome.
  9. Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis.
  10. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
  11. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.
  12. Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens.
  13. CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis.
  14. Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.
  15. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
  16. Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells.
  17. A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries.
  18. CROI 2016: Viral Hepatitis and Liver Fibrosis.
  19. Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda.
  20. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
  21. Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings.
  22. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.
  23. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
  24. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
  25. Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification.
  26. CROI 2015: Highlights of Viral Hepatitis Therapy.
  27. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
  28. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
  29. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
  30. CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy.
  31. HIV-associated central nervous system tuberculosis.
  32. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs.
  33. Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
  34. Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB.
  35. Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial.
  36. Household ventilation and tuberculosis transmission in Kampala, Uganda.
  37. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
  38. CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy.
  39. Complications of HIV disease and antiretroviral therapy.
  40. Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia.
  41. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
  42. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.
  43. Tuberculosis drug development: ensuring people living with HIV are not left behind.
  44. Complications of HIV disease and antiretroviral therapy.
  45. Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States.
  46. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata.
  47. Tuberculosis as part of the natural history of HIV infection in developing countries.
  48. Complications of HIV disease and antiretroviral treatment.
  49. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals.
  50. Antiretroviral therapy and TB.
  51. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients.
  52. Willing and able? Provision of medication for abortion by future internists.